Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Pentavalent Market CAGR Outlook And Future Development
The pentavalent market’s size has demonstrated steady growth in recent years. It will grow from $2.7 billion in 2025 to $2.83 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. This historical expansion can be attributed to increasing infant mortality rates, restricted access to vaccines, the widespread occurrence of rotavirus infections, government-led vaccination programs, and global public health initiatives.
The pentavalent market size is expected to experience consistent growth in the coming years. It is projected to reach $3.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.7%. This expansion during the forecast period can be attributed to technological advancements in vaccine development, increasing healthcare expenditure, the broadening of immunization programs in developing countries, partnerships between pharmaceutical companies, and the integration of digital tracking for vaccine coverage. Key trends anticipated in this period include an increase in infant immunization initiatives, government funding for vaccine research and development, the expansion of public health infrastructure, growing awareness of rotavirus prevention, and the development of cold chain logistics.
Get A Free Sample Report With In-Depth Market Insights:
Pentavalent Market Expansion Drivers: What’s Shaping Future Growth?
The increasing incidence of diphtheria is projected to bolster the expansion of the pentavalent market moving forward. Diphtheria is a severe and highly communicable illness caused by the bacterium Corynebacterium diphtheriae, which can lead to significant difficulties with eating and breathing, as well as the potential development of skin ulcers. The pentavalent vaccine offers protection to children against diphtheria through a three-dose immunization schedule, thus the rising prevalence of this disease has increased the demand for pentavalent vaccines. For instance, according to the European Centre for Disease Prevention and Control, a Europe-based government agency, in July 2025, a total of 126 laboratory-confirmed cases of C. diphtheriae ST574 were identified across Germany, including 55 cases in 2022, 49 cases in 2023, 18 cases in 2024, and at least 4 cases in 2025. Therefore, the growing prevalence of diphtheria is a key factor propelling the growth of the pentavalent market. The expanding healthcare spending is anticipated to stimulate the advancement of the pentavalent market. Healthcare expenditure refers to the aggregate financial and other resources allocated to the provision of health services over a specified duration. In the context of the pentavalent market, healthcare expenditure represents the financial resources dedicated to the development, production, distribution, and administration of vaccines that offer protection against five distinct diseases. For instance, the Centers for Medicare & Medicaid Services, a U.S.-based agency responsible for managing the Medicare and Medicaid programs, reported in December 2024 that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, which equates to approximately $14,570 per individual. Consequently, the uptick in healthcare expenditure is a significant factor driving the growth of the pentavalent market.
Pentavalent Market Segment Breakdown: Which Categories Lead On Revenue?
The pentavalent market covered in this report is segmented –
1) By Type: Pentavalent Vaccines (DTP-HepB-Hib combination), Other Combination Vaccines
2) By Formulation Type: Lyophilized, Liquid
3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Pentavalent Vaccines (DTP-HepB-Hib combination): DTP-HepB-Hib (Whole Cell), DTP-HepB-Hib (Acellular)
2) By Other Combination Vaccines: Hexavalent Vaccines
Pentavalent Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the pentavalent market are concentrating on developing innovative solutions, such as pentavalent immunization vaccines. These are combination vaccines designed to offer protection against five distinct diseases. For instance, in October 2023, Pfizer, a US-based pharmaceutical company, announced FDA approval for its ‘Penbraya’ pentavalent vaccine. This vaccine is the initial and sole pentavalent option providing protection against the five most prevalent meningococcal serogroups, namely A, B, C, W-135, and Y, for individuals aged 10 through 25 years. The vaccine merges elements from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. Penbraya has been identified as effective in providing protection against the five meningococcal serogroups responsible for the majority of global cases of invasive meningococcal disease.
Pentavalent Market Leading Players And Competitive Positioning
Major companies operating in the pentavalent market are Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.
View The Full Pentavalent Market Report:
Pentavalent Market Geographic Analysis: Where Is Demand Accelerating Fastest?
Asia-Pacific was the largest region in the pentavalent market in 2025. The regions covered in the pentavalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
